Lead Bookrunner on Perspective Therapeutics' Confidentially Marketed Public Offering

Oppenheimer & Co. Inc. acted as Lead Bookrunner on Perspective Therapeutics’ $69MM Confidentially Marketed Public Offering

Perspective Therapeutics, Inc. (“Perspective”) (NYSEAM: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced on Thursday the pricing of its underwritten public offering of 132,075,218 shares of its common stock at a price of $0.37 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 30,086,944 shares at a price of $0.369 per pre-funded warrant. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $60.0 million. Perspective granted the underwriters a 30-day option to purchase up to 24,324,324 additional shares of common stock at the public offering price, less underwriting discounts and commissions; the underwriters have exercised this option in full, resulting in a total offering size of $69.0 million.

Perspective recently announced it had begun recruitment for the second dosing cohorts in clinical studies for both of its lead programs: [²¹²Pb]VMT-α-NET and [²¹²Pb]VMT01. In addition, Perspective made two strategic announcements in early January: a co-development option arrangement with Lantheus Holdings for Perspective’s [²¹²Pb]VMT-α-NET program which included a $28.0 million upfront payment, and an exclusive license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate.